BRISTOL-MYERS SQUIBB INTRODUCES PRAVACHOL, A NEW CHOLESTEROL-LOWERING THERAPY
BRISTOL-MYERS SQUIBB INTRODUCES PRAVACHOL,
A NEW CHOLESTEROL-LOWERING THERAPY
NEW YORK, Nov. 1 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the introduction of Pravachol(R) (pravastatin sodium), an effective new drug to control elevated blood cholesterol levels. The product will be available in the United States for physician prescribing in the very near future.
Pravachol, a cholesterol synthesis inhibitor, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia when the response to a diet low in saturated fat and cholesterol alone is inadequate.
Pravachol is available as 10 mg and 20 mg tablets. Its convenient dosing, once-daily at bedtime with or without food, may contribute to increased patient compliance.
Bristol-Myers Squibb Company is a diversified pharmaceutical company whose principal businesses are pharmaceuticals, nutritionals, consumer products and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies and diagnostic agents.
/NOTE TO EDITORS: Bristol-Myers Squibb Company is planning a scientific briefing on Pravachol(R) (pravastatin sodium). Media will be alerted to details shortly./
/CONTACT: Robert F. Laverty of Bristol-Myers Squibb, 609-921-5551/
(BMY) CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU: PDT GK -- NY010 -- 0070 11/01/91 08:38 EST